The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum.
Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder that causes defects in the DNA repair system. It is characterized by a marked sensitivity to sunlight, and sufferers develop serious sunburns with onset of poikilodermia in the light-exposed skin. Squamous cell carcinomas, basal cell carcinomas (BCCs) and malignant melanomas appear in childhood. Two sisters with XP presented with previously treated facial BCCs. They were treated with imiquimod 5% cream three times weekly, one for 6 weeks and the other for 10 weeks. Although both sisters temporarily discontinued treatment due to severe erythema and erosion, successful long-term clearance was observed with no recurrences in both cases.
Roseeuw
D
D
Dermatology, Academic Hospital, Free University Brussels, Belgium.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002280:Basal Cell Carcinoma / Q000150:complications / Q000188:drug therapy*; D005153:Facial Neoplasms / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077271:Imiquimod; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014983:Xeroderma Pigmentosum / Q000150:complications*
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod